2731 results about "Tumor tissue" patented technology

A radiation machine incorporating a diagnostic imaging system is disclosed. The invention provides a very stable design of the machine by supporting an inner gantry part, including a treatment and diagnostic radiation source and detector, by an outer gantry part at two support locations situated at opposite sides of a treatment volume in a patient to be irradiated. This stable gantry design provides a high rotation speed of the inner gantry part relative the outer gantry part around the target volume, which speed is adapted for the high resolution imaging system. Based on the obtained images, changes and developments in tumor tissue and misplacement of patient may be detected. The images may be compared to a reference image to detect any anatomical or spatial difference therebetween. Based on this comparison the settings of the radiation machine may be adapted accordingly.

Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be over-expressed in gastric tumor tissue and other tumor tissue, and thus can be used as markers for gastric and other types of cancer. GTM proteins can be released from cancer cells, and can reach sufficiently high concentrations in the serum and / or other fluids to permit their detection. Thus, methods and test kits for detection and quantification of GTM can provide a valuable tool for diagnosis of gastric cancer.

A minimally-invasive fluid-cooled insertion sleeve assembly, with an attached balloon and distally-located penetrating tip, into which sleeve any of a group comprising a rigid rod, a microwave-radiator assembly and an ultrasonic-imaging transducer assembly may be inserted, constitutes a probe of the system. The sleeve assembly comprises spaced inner and outer plastic tubes with two fluid channels situated within the coaxial lumen between the inner and outer tubes. The fluid coolant input flows through the fluid channels into the balloon, thereby inflating the balloon, and then exits through that coaxial lumen. An alternative embodiment has no balloon. The method employs the probe for piercing sub-cutaneous tissue and then ablating deep-seated tumor tissue with microwave-radiation generated heat.

A system is provided for treating tumor tissue sites of a patient. At least first and second mono-polar electrodes are configured to be introduced at or near the tumor tissue site of the patient. A voltage pulse generator is coupled to the first and second mono-polar electrodes. The voltage pulse generator is configured to apply sufficient electrical pulses between the first and second mono-polar electrodes to induce electroporation of cells in the tumor tissue site, to create necrosis of cells of the tumor tissue site, but insufficient to create a thermal damaging effect to a majority of the tumor tissue site.

The present invention relates to the field of biomedical engineering and medical treatment of diseases and disorders. Methods, devices, and systems for in vivo treatment of cell proliferative disorders are provided. In embodiments, the methods comprise the delivery of high-frequency bursts of bipolar pulses to achieve the desired modality of cell death. More specifically, embodiments of the invention relate to a device and method for destroying aberrant cells, including tumor tissues, using high-frequency, bipolar electrical pulses having a burst width on the order of microseconds and duration of single polarity on the microsecond to nanosecond scale. In embodiments, the methods rely on conventional electroporation with adjuvant drugs or irreversible electroporation to cause cell death in treated tumors. The invention can be used to treat solid tumors, such as brain tumors.

Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.

A system is provided for treating tumor tissue sites of a patient. At least first and second mono-polar electrodes are configured to be introduced at or near the tumor tissue site of the patient. A voltage pulse generator is coupled to the first and second mono-polar electrodes. The voltage pulse generator is configured to apply sufficient electrical pulses between the first and second mono-polar electrodes to induce electroporation of cells in the tumor tissue site, to create necrosis of cells of the tumor tissue site, but insufficient to create a thermal damaging effect to a majority of the tumor tissue site.

A minimally-invasive fluid-cooled insertion sleeve assembly, with an attached balloon and distally-located penetrating tip, into which sleeve any of a group comprising a rigid rod, a microwave-radiator assembly and an ultrasonic-imaging transducer assembly may be inserted, constitutes a probe of the system. The sleeve assembly comprises spaced inner and outer plastic tubes with two fluid channels situated within the coaxial lumen between the inner and outer tubes. The fluid coolant input flows through the fluid channels into the balloon, thereby inflating the balloon, and then exits through that coaxial lumen. An alternative embodiment has no balloon. The method employs the probe for piercing sub-cutaneous tissue and then ablating deep-seated tumor tissue with microwave-radiation generated heat.

The present invention relates to photosensitizer immunoconjugate compositions and combination therapies for use in cancer related photodynamic treatments and diagnostic methods. Photosensitizer immunoconjugates comprising a photosensitizer conjugated to a tumor-specific and / or tumoricidial antibody and processes for the preparation thereof are described. The use of photosensitizer immunoconjugates (PICs) offers improved photosensitizer delivery specificity for diagnostic and therapeutic applications. Combination therapies to co-localize activated photosensitizer compounds and tumoricidal antibodies in tumor tissues are also described.

An implantation device for implanting miniature radioactive source in the tumor tissue features that a small and light radioactive source storage cabin able to be separated from the implantation cabin of radioactive source is used. Its advantages are easy operation and easy supplement of radioactive source.

The present invention provides a bacterium belonging to the genus Bifidobacterium, by which DNA coding for a protein having an antitumor activity or DNA coding for a protein having the activity of converting a precursor of an antitumor substance into the antitumor substance is delivered to tumor tissues specifically under anaerobic conditions thereby expressing the protein encoded by the DNA, as well as a pharmaceutical composition comprising said anaerobic bacterium.

The present invention relates to photosensitizer immunoconjugate compositions and combination therapies for use in cancer related photodynamic treatments and diagnostic methods. Photosensitizer immunoconjugates comprising a photosensitizer conjugated to a tumor-specific and / or tumoricidial antibody and processes for the preparation thereof are described. The use of photosensitizer immunoconjugates (PICs) offers improved photosensitizer delivery specificity for diagnostic and therapeutic applications. Combination therapies to co-localize activated photosensitizer compounds and tumoricidal antibodies in tumor tissues are also described.

Radiofrequency ablation (RFA) may be used as a minimally invasive treatment of solid tumors, typically cancers of the liver, lung, breast, kidney and bone, most often via a percutaneous approach. In RFA tumor tissue is killed by heating. RFA requires guidance using an imaging method to correctly position the RF applicator. Magnetic resonance imaging (MRI) can be used for guidance, and offers the additional advantage of the ability to image tissue temperature. Because MRI employs high power RF fields, the MRI scanner could serve as the source of RF energy for ablation. Described herein are an MRI-driven RF ablation device and method. The device has minimal electrical circuitry, and uses the MR scanner radio frequency field as the energy source to generate heat in tissue using an antenna and a needle. Based on the Faraday induction law, different embodiments for coupling the body coil RF energy into tissue are disclosed.

The present invention provides methods using a gene expression profiling analysis (1) to determine whether a human sample is a tumor using a gene set containing nucleic acid sequences of SEQ ID NOS: 1-7, 8-17 or 1-17; (2) to identify whether a tumor tissue is an adenocarcinoma (using a gene set containing nucleic acid sequences of SEQ ID NOS: 15, and 18-21) or a squamous cell carcinoma (using a gene set containing nucleic acid sequences of SEQ ID NOS: 22-27); and (3) to predict the prognosis of survival and metastasis in humans with tumor (using a gene set containing nucleic acid sequences of SEQ ID NOS:19, and 28-42 or SEQ ID NOS: 19, 29, 31, 40, and 42), particularly for those humans who are at the early stage of lung cancer. The gene expression profiling is preferably performed by cDNA microarray-based techniques and / or Real-Time Reverse Transcription-Polymerase Chain Reaction (Real-Time RT-PCR), and analyzed by statistical means.

An instrument for electrochemical treatment of the human body or of an animal body is disclosed. The instrument is useful for the destruction of tumor tissues. One or several electrodes are furnished for insertion into the body to be treated. A direct current generator (1) generates a DC voltage. Connection lines (2,3,3′) for the generated direct current power are connectable to the generator. A switching box (9) inserted into the connection lines for a selection of electrode polarity. At least one trocar sleeve (7,7′) is connected with a first end to the connection lines., At least one trocar thorn (12) is insertable into the trocar sleeve. At least one electrode (5,5′) is insertable into the trocar sleeve such that an end of the electrode (5,5′) protrudes from a second end of the trocar sleeve. Tumors having sizes up to about 50 centimeters diameter can be treated with the instrument.

The invention is related to the instrument for measuring a Raman signal of tissue, the instrument comprising a laser, a signal detection unit for measuring the Raman signal, and a fiber optic probe, wherein the fiber optic probe comprises one or more optical fibers for directing laser light onto the tissue and for collecting light that is scattered by the tissue and guiding the collected light away from the tissue towards the signal detection unit, wherein the fiber or fibers for collecting light have substantially no Raman signal in one or more parts of the 2500-3700 cm−1 spectral region, and wherein the detection unit records the Raman signal scattered by the tissue in said spectral region. The invention enables ex vivo, in vitro and in vivo analysis and diagnosis of atherosclerotic plaque and detection of tumor tissue with great advantages over current state-of-the-art technology.

The present invention relates to the field of biomedical engineering and medical treatment of diseases and disorders. Methods, devices, and systems for in vivo treatment of cell proliferative disorders are provided. In embodiments, the methods comprise the delivery of high-frequency bursts of bipolar pulses to achieve the desired modality of cell death. More specifically, embodiments of the invention relate to a device and method for destroying aberrant cells, including tumor tissues, using high-frequency, bipolar electrical pulses having a burst width on the order of microseconds and duration of single polarity on the microsecond to nanosecond scale. In embodiments, the methods rely on conventional electroporation with adjuvant drugs or irreversible electroporation to cause cell death in treated tumors. The invention can be used to treat solid tumors, such as brain tumors.

A method, using high intensity ultrasound, which may also be combined with a chemotherapy agent, that can result the direct destruction of tumor cells and in the reduction or elimination of local reoccurrence of cancer after removal of cancerous tissue, such as a surgical breast lumpectomy or surgical excision of a brain tumor. The method comprises either (1) the treatment of the tumor directly with High Intensity Focused Ultrasound, or (2) the treatment of the margins of the tissue surrounding the surgical cavity or void with ablative continuous wave high intensity ultrasound and a combination of a locally delivered chemotherapy agent and high intensity ultrasound, termed sonoporation. The present invention permits both the direct destruction (ablation) of tumor tissue as well as the destruction of tissue around the surgical margin and may include the enhanced local cellular uptake of locally injected chemotherapeutic drugs, all of which can be accomplished by a therapeutic ultrasound device used during surgery.

The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC). The labeled amino acid compounds of the invention are useful as imaging agents in detecting and / or monitoring tumors in a subject by PET or SPECT.

The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and / or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.

According to the invention, compositions are made available which have a strong cytotoxic effect which is largely selective on tumor tissue. The invention is based on the fact that certain benzoic acid derivatives have a strong synergistic effect as a mixture and destroy cancer cells selectively in a pH range of 7 or below, such as from 6.5 to 7.

A system associated with quantifying a density level of tumor-infiltrating lymphocytes, based on prediction of reconstructed TIL information associated with tumoral tissue image data during pathology analysis of the tissue image data is disclosed. The system receives digitized diagnostic and stained whole-slide image data related to tissue of a particular type of tumoral data. Defined are regions of interest that represents a portion of, or a full image of the whole-slide image data. The image data is encoded into segmented data portions based on convolutional autoencoding of objects associated with the collection of image data. The density of tumor-infiltrating lymphocytes is determined of bounded segmented data portions for respective classification of the regions of interest. A classification label is assigned to the regions of interest. It is determined whether an assigned classification label is above a pre-determined threshold probability value of lymphocyte infiltrated. The threshold probability value is adjusted in order to re-assign the classification label to the regions of interest based on a varied sensitivity level of density of lymphocyte infiltrated. A trained classification model is generated based on the re-assigned classification labels to the regions of interest associated with segmented data portions using the adjusted threshold probability value. An unlabeled image data set is received to iteratively classify the segmented data portions based on a lymphocyte density level associated with portions of the unlabeled image data set, using the trained classification model. Tumor-infiltrating lymphocyte representations are generated based on prediction of TIL information associated with classified segmented data portions. A refined TIL representation based on prediction of the TIL representations is generated using the adjusted threshold probability value associated with the classified segmented data portions. A corresponding method and computer-readable device are also disclosed.

The invention belongs to the field of pharmaceutical agents, relates to a polymer micelle lyophilized agent encapsulating an insoluble antitumor drug as well as a preparation method and an application thereof. The polymer micelle lyophilized agent is prepared by carrying out molecular self-assembly on a methoxy poly(ethylene glycol) 2000-polyester block copolymer to form micelles, and then encapsulating the insoluble antitumor drug in a hydrophobic core formed by the polyester. The lyophilized agent has high encapsulation rate, high drug loading and small particle size, can significantly improve the water solubility of the insoluble drug and result in passive targeting of more antitumor drugs to concentrate in the tumor tissues, thus improving an anti-tumor treatment effect and reducing the toxic and side effects of drugs, and can be used to prepare the drugs used for the treatment of lung cancer, intestinal cancer, mammary cancer, ovarian cancer, etc. The lyophilized agent can also be quickly dissolved and dispersed to form a transparent micellar solution after water for injection, normal saline solution and the like are added, and is used for the preparation of the drugs for treating primary intestinal cell carcinoma.

The present invention describes a method utilizing a set of genes or gene products whose altered expression in cancer tissue, particularly head and neck cancer and other carcinomas, or its adjacent normal tissues predicts (a) probability of recurrence in time after treatment (b) sensitivity or resistance to therapies or (c) probability of metastasis at the time of initial discovery of the tumor. Furthermore, the invention describes methods of determining the molecular signature in tumor tissues, tissues adjacent to the tumor, or in saliva by using DNA microarray techniques, quantitative real-time PCR, immunohistochemistry or other methods that are used for determining gene or gene product expression levels.

The invention relates to modification of a cell penetrating peptide for realizing a low-toxicity administration system with a positive targeting selecting function. A shielding peptide, an enzymolysis substrate peptide and a cell-penetrating peptide are connected in sequence, so that an activatable cell penetrating peptide is formed; and a medicament and / or a tracer and / or a medicament carrier is connected or embedded or adsorbed to the cell penetrating peptide, so that an administration system is constructed. According to a shielding peptide sequence, positive charges carried on the surface of the administration system can be reduced or completely neutralized, the cell penetrating capability of the cell penetrating peptide is shielded, and the toxicity of the administration system on normal cells of an organism is lowered; and an enzymolysis substrate peptide sequence can be identified by enzyme systems secreted specifically by different pathological change tissue cells and fractured by enzyme hydrolysis, so that a cell penetrating peptide is released and is used for carrying a medicament and / or a medicament carrier through a cell membrane, and the medicament enters cells and is brought into play. The invention aims to actively convey an antitumor medicament to tumor tissues in a targeted way and make the antitumor medicament enter tumor cells to a larger extent by using the administration system which can be used for activating a cell penetrating function, so that the toxicity at a non-tumor position is lowered while the antitumor effect of the medicament is enhanced.

The invention comprises a method for removal of tumor tissue from a patient's body. The method generally comprises the steps of providing an apparatus comprising an elongate member for receiving tissue. The elongate member defines a lumen and comprises a distal end defining an aperture and a proximal end. The apparatus further comprises an elongate tissue removal member for conveying tissue through the lumen. The tissue removal member is rotatably disposed within the lumen. The method further comprises gathering a sample of said tissue into said lumen; and conveying with said tissue removal member at least a portion of the tissue sample proximally along said lumen. The step of gathering may be accomplished by advancing the apparatus through the tissue.

The invention discloses an in vitro culture method of a colorectal cancer organoid. The in vitro culture method comprises: 1) pretreatment of colorectal cancer biopsy tissue: washing colorectal cancerbiopsy tissue, shearing, and digesting with enzyme to obtain colorectal cancer single cell; and 2) in vitro culture of the colorectal cancer single cell: mixing the colorectal cancer single cell andmatrigel, solidifying, adding a colorectal cancer organoid culture liquid, and culturing to obtain the colorectal cancer organoid. According to the present invention, the method has characteristics ofsimpleness, good stability and high success rate; and the obtained colorectal cancer organoid has a three-dimensional structure, substantially retains the unique morphological characteristics of thepatient tumor tissue, is highly consistent with the pathological features of the biopsy tissue, and provides the material basis for the establishment of the organoid library and the screening of drugs.

The invention relates to a common carrier material based on graphene oxide for a targeting anticancer drug and a gene and application and application. Folic acid, lactobionic acid and other tumor cell targeting or liver targeting molecules and part of amino groups of soluble chitosan are connected by amide bonds to prepare a conjugate, the conjugate is then connected with graphene oxide, quaternization is performed by using an epoxy compound with a quaternary ammonium group, and gene molecules are loaded by the quaternizationquaternized part of the chitosan through electrostatic attraction; and then the anticancer drug is loaded by pi-pi conjugates, hydrogen bonds and hydrophobic effects in a non-covalent bond method. By adopting the targeting performance of targeting molecules and effects of graphene oxide of a particular size to enhance penetration and retention in tumor tissues and combining the performance of the graphene oxide for pH response control release of the loaded drug, the drug can be realized released in a tumor cell, an intelligent delivery system for the common carrier of the tumor targeting or liver targeting anticancer drug and the gene is synthesized from the perspective of synergetic medication, and a theoretical basis and a method basis are provided for combined therapy of tumor.

There is disclosed an improved high-throughput and quantitative process for determining methylation patterns in genomic DNA samples based on amplifying modified nucleic acid, and detecting methylated nucleic acid based on amplification-dependent displacement of specifically annealed hybridization probes. Specifically, the inventive process provides for treating genomic DNA samples with sodium bisulfite to create methylation-dependent sequence differences, followed by detection with fluorescence-based quantitative PCR techniques. The process is particularly well suited for the rapid analysis of a large number of nucleic acid samples, such as those from collections of tumor tissues.